Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

ment projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize REOLYSIN(R), uncertainties related to the research, development and manufacturing of pharmaceuticals, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake to update these forward-looking statements.

OVERVIEW

Oncolytics Biotech Inc. is a Development Stage Company

Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of REOLYSIN(R), our potential cancer therapeutic. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, if and when, our cancer product becomes commercially viable.

General Risk Factors

Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based upon studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be develo
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 2015 BioNorth Texas (BioNorthTX), an ... the life sciences industry in northern region of ... at The Foundry in Dallas on April 27, ... together a broad spectrum of biotech professionals from ... early successes in partnering with key life sciences ...
(Date:5/28/2015)... Biscayne Pharmaceuticals, Inc ., today announced ... hormone-releasing hormone (GHRH) technology will be discussed in a ... The data show that the family of receptors for ... present on many primary breast cancer cells regardless of ... could have broad anti-cancer potential in breast cancer. 1 ...
(Date:5/28/2015)... 2015 The Fertility Centers of New ... Danielle Vitiello has taken on a new and expanded ... will provide guidance, leadership, oversight and quality assurance for ... Vitiello among our team of experienced reproductive endocrinologists,” said ... A. Hill, M.D. “Her expertise and compassionate, individualized care ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... NORTH VANCOUVER, April 16 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ... on its on-going restructuring efforts., The Board of ... stepped down as President and Chief Executive Officer, effective,immediately. ... Mr. Duncan, a,founder of the Company, served as President ...
... Annual Meeting of the American ... Association for Cancer Research (AACR) -, ... LOR; AMEX: LRP), a biopharmaceutical company specializing,in the research, ... management of cancer, today announced,presentations of further preclinical data ...
... the National Institute of Standards and Technology (NIST) ... on a single microchip, a cryogenic sensor and ... cheaper, simpler and faster precision analysis of materials ... in an upcoming issue of Applied Physics Letters,* ...
Cached Biology Technology:Chromos provides shareholder update 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 3Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 4NIST micro sensor and micro fridge make cool pair 2
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/6/2015)... Israel , May 6, 2015 LifeBEAM, ... most established helmet producer, announced today that they will ... Helmet, the world,s first bio-sensing cycling helmet and the ... released in two new colors in order to give ... the product. In addition, LifeBEAM and Lazer announced their ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... that proteins on the surface of a cell twist a ... and cause disease, all in a movement as graceful as ... issue of Nature Structural & Molecular Biology . ... biologist, describes the crucial initial steps taken by attachment proteins ...
... a compound in grapes, displays antioxidant and other positive ... the UT Health Science Center San Antonio describe a ... effects. Resveratrol stimulates the expression of adiponectin, a ... the team found. Adiponectin has a wide range of ...
... in the United States do not grasp the scientific ... in understanding the causes and consequences of climate change, ... BioScience . The study, whose authors include ... calls for a new way of teaching and, ...
Cached Biology News:Mayo researchers describe measles viral protein movement 2Grape ingredient resveratrol increases beneficial fat hormone 2College students lack scientific literacy, study finds 2
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Prim...
Request Info...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Biology Products: